Pacira BioSciences, Inc.PCRX stock score: 65/100
$36.48 · +0.00% · Scored Nov 19, 2026
- Technical
- 63
- Fundamental
- 65
- News
- 56
The reading
Pacira BioSciences (PCRX) scores 65 out of 100, which reads neutral, higher than 90% of Healthcare stocks and 90% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 65, technicals 63.
Among the fundamentals, Earnings Growth (Annual) at 100 and Current Ratio at 99 score highest, while Return on Equity (ROE) at 4 weighs the most against it.
News sentiment is neutral at 56; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 48 to 65, and it is up 14 points over the period.
About Pacira BioSciences
Pacira BioSciences (PCRX) is a U.S. pharmaceutical company focused on non-opioid treatments for pain. Its largest product is EXPAREL, a long-acting form of the local anesthetic bupivacaine that surgeons and anesthesiologists inject at the time of surgery to control pain for several days and reduce the need for opioids afterward. Its second product, ZILRETTA, is an extended-release steroid injection for osteoarthritis knee pain, and Pacira is testing it in shoulder osteoarthritis as well. The company sold its iovera cold-based nerve treatment business to Zimmer Biomet and is developing a gene therapy candidate for knee osteoarthritis. Customers are hospitals, ambulatory surgery centers and orthopedic practices, with reimbursement from Medicare and commercial insurers, some of which now pay separately for non-opioid pain drugs used in outpatient surgery. Pacira earns money from product sales through specialty distributors and wholesalers.
Pacira competes with generic bupivacaine and other local anesthetics, with Heron Therapeutics’ Zynrelef, with opioids and newer non-opioid painkillers, and in knee pain with generic steroids and hyaluronic acid injections. Its edge rests on clinical data and long experience with EXPAREL across many surgical procedures and an established hospital sales force. Investors who follow PCRX stock tend to watch EXPAREL sales and volume growth. Reimbursement changes that encourage non-opioid pain treatment are closely followed. ZILRETTA trial results, patent challenges and possible generic competition, debt and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward PCRX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
65Pulling it up
Net income growth from the prior fiscal year to the latest.
Current assets divided by current liabilities: the ability to pay short-term bills.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Holding it back
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Operating margins measure profitability after operating expenses.
Return on total capital: net income divided by debt plus equity, for the latest year.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
—Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Where the price sits between its 52-week low and high.
The price change over the last 52 weeks.
Holding it back
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.
SPY SMA 10 evaluates the S&P 500 (SPY) position relative to its 10-period simple moving average.
10 weighted scorers; 55 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 56
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 45 | 1 |
| Monthly | 68 | 2 |
| Quarterly | 66 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 65 |
| Nov 18, 2026 | 64 |
| Nov 17, 2026 | 64 |
| Nov 16, 2026 | 64 |
| Nov 15, 2026 | 64 |
| Nov 14, 2026 | 64 |
| Nov 13, 2026 | 64 |
| Nov 12, 2026 | 64 |
| Nov 11, 2026 | 60 |
| Nov 10, 2026 | 60 |
| Nov 7, 2026 | 60 |
| Nov 6, 2026 | 60 |
| Nov 5, 2026 | 59 |
| Nov 4, 2026 | 59 |
| Nov 3, 2026 | 60 |
| Nov 2, 2026 | 60 |
| Nov 1, 2026 | 59 |
| Oct 30, 2026 | 60 |
| Oct 29, 2026 | 60 |
| Oct 28, 2026 | 60 |
| Oct 27, 2026 | 60 |
| Oct 26, 2026 | 60 |
| Oct 25, 2026 | 60 |
| Oct 24, 2026 | 60 |
| Oct 23, 2026 | 60 |
| Oct 22, 2026 | 60 |
| Oct 21, 2026 | 60 |
| Oct 20, 2026 | 61 |
| Oct 19, 2026 | 60 |
| Oct 18, 2026 | 60 |
| Oct 17, 2026 | 60 |
| Oct 16, 2026 | 60 |
| Oct 15, 2026 | 60 |
| Oct 14, 2026 | 60 |
| Oct 13, 2026 | 61 |
| Oct 12, 2026 | 60 |
| Oct 11, 2026 | 61 |
| Oct 10, 2026 | 61 |
| Oct 9, 2026 | 60 |
| Oct 8, 2026 | 60 |
| Oct 7, 2026 | 56 |
| Oct 6, 2026 | 52 |
| Oct 5, 2026 | 54 |
| Oct 4, 2026 | 55 |
| Oct 3, 2026 | 55 |
| Oct 2, 2026 | 54 |
| Oct 1, 2026 | 53 |
| Sep 30, 2026 | 54 |
| Sep 29, 2026 | 55 |
| Sep 28, 2026 | 55 |
| Sep 27, 2026 | 55 |
| Sep 26, 2026 | 55 |
| Sep 25, 2026 | 55 |
| Sep 24, 2026 | 54 |
| Sep 23, 2026 | 53 |
| Sep 22, 2026 | 51 |
| Sep 21, 2026 | 49 |
| Sep 20, 2026 | 50 |
| Sep 19, 2026 | 50 |
| Sep 18, 2026 | 50 |
| Sep 17, 2026 | 49 |
| Sep 16, 2026 | 50 |
| Sep 15, 2026 | 48 |
| Sep 14, 2026 | 50 |
| Sep 13, 2026 | 52 |
| Sep 12, 2026 | 52 |
| Sep 11, 2026 | 52 |
| Sep 10, 2026 | 52 |
| Sep 9, 2026 | 53 |
| Sep 8, 2026 | 54 |
| Sep 7, 2026 | 55 |
| Sep 6, 2026 | 55 |
| Sep 5, 2026 | 55 |
| Sep 4, 2026 | 55 |
| Sep 2, 2026 | 56 |
| Sep 1, 2026 | 55 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 55 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 55 |
| Aug 25, 2026 | 54 |
| Aug 24, 2026 | 53 |
| Aug 23, 2026 | 51 |
Key facts
- Market cap
- $1.5B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.22
- Risk grade (1–10)
- 5
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| ETON Eton Pharmaceuticals | $1.8B | 63 |
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| ALVO Alvotech | $1.5B | 55 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| HROW Harrow | $1.2B | 57 |
| AMPH Amphastar Pharmaceuticals | $1.2B | 62 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is PCRX's stock rating today?
PCRX scores 65/100 (Neutral) as of Nov 19, 2026: technical 63, fundamental 65, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.
What does Pacira BioSciences do?
Pacira BioSciences (PCRX) is a U.S. pharmaceutical company focused on non-opioid treatments for pain.
Is PCRX stock a buy?
The score is not a buy or sell recommendation. A 65 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the PCRX score calculated?
47 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 10 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/pcrx/"><img src="https://stocksscores.com/stocks/pcrx/badge.svg" alt="PCRX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/pcrx/)